share_log

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target

Benzinga ·  Sep 22, 2023 10:54

RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $51 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment